- Angelika Bischof Delaloye, University of Lausanne
"EJNMMI Research aims to be a platform of lively scientific exchange on new findings in basic, translational and clinical research in nuclear medicine and related matters. It addresses research in biology and medicine together with radiochemistry, radiopharmacy, radiophysics, dosimetry and instrumentation. The open access model speeds up the publication process and therefore favours rapid communication of new scientific results, even if still preliminary. Manuscripts are accepted for publication only after thorough peer review.
EJNMMI Research has been launched by Springer as a companion journal to the EJNMMI and not as a competitor. It offers space to authors whose manuscripts, despite high quality, cannot be accommodated by the EJNMMI. Consequently, authors of original manuscripts rejected by the EJNMMI are encouraged to submit their work to EJNMMI Research.
The journal also offers the possibility to publish reviews, short communications and selected case reports. Educational papers set out to improve and expand understanding and knowledge in particularly active research domains. Editorials and letters complete the exchange of views and ideas. We also welcome submission of well-designed studies that did not confirm the initial hypothesis, as we are convinced that they contribute to the advancement of science and should therefore be made available to the scientific community"
Angelika Bischof Delaloye,
University of Lausanne
Aims & scope
EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies.
The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.
SpringerOpen is Springer’s new suite of open access journals which will cover all disciplines. SpringerOpen journals are fully and immediately open access and will publish articles under the Creative Commons Attribution license. This makes it easy for authors to fully comply with open access mandates and retain copyright. SpringerOpen journals combine open access and our expertise in delivering high-quality and rapid publications, from online submission systems and in-depth peer review to an efficient, author-friendly production process.
- Google Scholar
- PubMed Central
- Summon by Serial Solutions